A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma

Published:2012-04 Issue:4 Volume:23 Page:997-1005
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chia W.K.,Wang W.-W.,Teo M.,Tai W.M.,Lim W.T.,Tan E.H.,Leong S.S.,Sun L.,Chen J.J.,Gottschalk S.,Toh H.C.

Funder

Singapore Cancer Syndicate

National Institute of Health grant

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/4/997/13785443/mdr341.pdf

Reference40 articles.

1. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal;Chang;Virus Res,2009

2. Nasopharyngeal carcinoma;Chan;Ann Oncol,2002

3. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century;Mould;Br J Radiol,2002

4. Epstein-Barr virus in the pathogenesis of NPC;Raab-Traub;Semin Cancer Biol,2002

5. Epstein-Barr virus: 40 years on;Young;Nat Rev Cancer,2004

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small extracellular vesicle CA1 as a promising diagnostic biomarker for nasopharyngeal carcinoma;International Journal of Biological Macromolecules;2024-08

2. Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies;Biomarker Research;2024-07-29

3. Treatment of Epstein-Barr Virus infection in immunocompromised patients;Biochemical Pharmacology;2024-07

4. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma – A Systematic Review and Meta-analysis;Oral Oncology;2024-05

5. Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis;Human Vaccines & Immunotherapeutics;2024-03-27